Close menu

February 4th, 2022 | 12:22 CET

Novavax, Cardiol, MorphoSys - Here's the second wave of Corona vaccine plays!

  • Cannabis
Photo credits:

The number of new Corona infections reported to the Robert Koch Institute (RKI) within one day has reached an all-time high. 236,120 additional cases were recorded, bringing the number of people in Germany who were confirmed to be infected with Sars-CoV-2 to 10.4 million. However, the number of unreported cases is significantly higher. Vaccine manufacturers from the early days have been able to clear the table in recent months, and now new companies such as Novavax and Valneva are entering the scene. But not all innovative approaches to fighting Corona are on the radar of investors. These are perfect conditions for a second share price wave.

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: NOVAVAX INC. DL-_01 | US6700024010 , CARDIOL THERAPEUTICS | CA14161Y2006 , MORPHOSYS AG O.N. | DE0006632003

Table of contents:

    Novavax - Vaccine deliveries to start soon in Germany

    There is good news for the shareholders of the US vaccine manufacturer. The Standing Committee on Vaccination (STIKO) recommends vaccination with Novavax for adults, and the vaccine is to be delivered in Germany from February 21. STIKO also instructs an administration of two doses at least three weeks apart. The European Medicines Agency puts the efficacy for protecting against corona infection with symptoms at 90%. However, it is unclear whether the Novavax vaccine is also effective against the Omicron variant.

    Great hopes are pinned on the Novavax vaccine and even more so on the preparation from Valneva (inactivated vaccine). Different approaches to the mRNA vaccines currently available on the market are expected to convince vaccination skeptics. With the American vaccine, no messenger substances are injected from which the body must first produce antigens; instead, the antigens are administered directly in the form of proteins, after which the body can immediately begin producing antibodies. With a market capitalization of USD 6.8 billion, the Company is only a fraction of the market capitalization of BioNTech and Moderna.

    Cardiol Therapeutics - Unrealized potential - for how much longer?

    The Corona vaccine manufacturers, BioNTech and Moderna, made a lot of money in the last few months due to their fast market presence. The (upcoming) vaccine deliveries of Novavax and Valneva are a competition for the top dogs that should not be underestimated. However, the addressable market is enormous and leaves enough room for many suppliers.

    Corona is of central importance for Canadian Cardiol Therapeutics. However, the Company's perception of the capital market and its valuation still leave much to be desired. The Company is currently undergoing promising clinical trials with preparations based on cannabidiol to treat (inflammatory) heart disease. In the US alone, USD 30 billion in costs are incurred annually related to heart disease. Damage to the heart is also one of the serious side effects of Corona vaccines or potential late effects of influenza disease.

    Recent research shows that ingredients in cannabis can prevent Coronavirus infection by blocking its entry into cells. This could give Cardiol preparations blockbuster potential. Analysts unanimously believe that the shares, which are also listed on the NASDAQ, have the potential to multiply. The stock market valuation is moderate at around CAD 141 million, the equivalent of just under EUR 98 million. CEO David Elsley will provide an update on current developments at the International Investment Forum (IIF), which opens its virtual doors on February 17, 2022. Registration is free of charge. For more information, please visit

    MorphoSys - Short breather?

    MorphoSys is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for people with cancer and autoimmune diseases. In recent months, the shares have gone steeply downhill, and over the year, investors lost more than 70% of capital invested. The share has stabilized at a low level below the EUR 30 mark in recent days.

    The Company is undergoing a transformation process, moving away from being a contract researcher for the pharmaceutical industry to becoming a developer of its own drugs. So far, however, only one cancer drug is on the market. The Company will be in the red in the next few years on the way to the expected market launch of the new drugs from 2025. R&D expenditures are increasing significantly. More than EUR 300 million is budgeted this year.

    Analysts view last year's billion-dollar acquisition of US-based Constellation Pharma with one eye laughing and the other crying. The expansion of the business model through epigenetics makes sense. Still, the takeover means that a high-risk pipeline has been acquired and that extensive license payments will have to be made in the future to the new investor Royalty Pharma, which put EUR 100 million on the table in the course of a capital increase.

    The battle against Corona is an ongoing issue. Away from the established suppliers, there are opportunities with Novavax. The potential of Cardiol is completely underestimated. Ingredients of cannabis can prevent infection with the coronavirus by blocking its entry into cells. MorphoSys still has a rocky road ahead of it.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author

    Related comments:

    Commented by Carsten Mainitz on January 18th, 2022 | 13:07 CET

    Ayurcann, Novavax, Covestro - The stragglers are coming!

    • Cannabis

    Humanity continues to find itself in the clutches of the Corona pandemic, the infection figures are rising, and the demand from politicians for mandatory vaccination is becoming louder and louder. While BioNTech and Pfizer vaccines and Moderna have dominated to date, new vaccine manufacturers are entering the market in the next wave. The situation is similar in the cannabis industry. After a boom about 3 years ago, the market leaders have since lost up to 80% of their value. Legalization and the rise of Cannabis 3.0. will pave the way for new companies.


    Commented by Stefan Feulner on January 12th, 2022 | 12:54 CET

    Tilray, Ayurcann, Aurora Cannabis - When will the boom 2.0 come?

    • Cannabis

    About five years ago, the boom of cannabis stocks started. Companies like Aurora Cannabis, Canopy Growth and Tilray were able to multiply within a few months. However, the boom was followed by a quick end on the stock market. With corrections of 90% in some cases, the exaggerations were harshly corrected. However, the cannabis market is still in a strong growth phase. The legalization in many countries and the cannabis 3.0 wave promise the companies enormous growth leaps in the next few years. Thus, the steep rise seen at the time could be repeated, at least to some extent.


    Commented by Stefan Feulner on December 28th, 2021 | 07:10 CET

    Upcoming hydrogen and cannabis boom - Nel ASA, Ayurcann, Canopy Growth

    • Cannabis

    These two completely different sectors have one thing in common. After both cannabis stocks and hydrogen sector companies multiplied in the past, a significant correction set in during the stock market year soon ending. This correction is likely to continue into the new year 2022. In the long term, however, there are outstanding opportunities both for cannabis, through legalization in various European countries, and for hydrogen, urgently needed for the energy transition. It is time to position yourself.